行情

HSGX

HSGX

Histogenics
NASDAQ

实时行情|Nasdaq Last Sale

0.2210
+0.0031
+1.42%
已收盘, 18:49 09/17 EDT
开盘
0.2110
昨收
0.2179
最高
0.2255
最低
0.2100
成交量
549.83万
成交额
--
52周最高
1.430
52周最低
0.0800
市值
2,090.65万
市盈率(TTM)
1.147
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

HSGX 新闻

  • 德意志银行:年底标普500将大跌13%至2600点
  • 新浪财经综合.3小时前
  • 欧洲8月份汽车销量大幅下滑 行业困境加剧
  • 新浪财经综合.3小时前
  • “脸书”新设独立监督委员会 可否决扎克伯格意见
  • 中国新闻网.3小时前
  • 德国8月纯电动汽车销量同比飙升逾一倍
  • 新浪财经综合.4小时前

更多

所属板块

制药
+0.65%
制药与医学研究
+0.57%

热门股票

名称
价格
涨跌幅

HSGX 简况

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient's own cartilage cells through a series of tissue engineering processes. The patient's cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company's Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.
展开

Webull提供Histogenics Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。